For Green Week, we're headed to Far Far Away to go over the history of the Shrek franchise's many, many tie-in video games.

A daring YouTuber managed to boot Windows 98 onto a 2000 internet appliance, turning a dial‑up box into a quirky PC.

Devices that were limited to only run a web browser were relatively common around 2000, as many people wanted to surf the ...

(UroToday.com) The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, IL, was host to the Poster Session: Genitourinary Cancer - Kidney and Bladder. Dr. Patrizia ...

ASCEND to evaluate CR-001, a PD-1 x VEGF bispecific antibody, in multiple solid tumor types, including NSCLC and gastrointestinal and gynecological cancers in first-line and previously treated ...

AstraZeneca is taking its oral GLP-1 drug into phase 3 on the back of a pair of midstage weight loss wins, despite remaining tight-lipped on how the candidate actually performed. The U.K.-based Big ...

First-in-human DS3790 trial tests a CD37-targeted ADC for relapsed/refractory B-cell non-Hodgkin lymphoma, aiming to improve response durability and survival. In a milestone for the hematologic ...

NEO-811 is a novel molecular glue degrader intended to fully block a key clear cell renal cell carcinoma signaling pathway via cereblon-dependent target degradation. The primary outcome measures for ...

Opus Genetics is conducting a trial for OPGx-MERTK gene therapy in Abu Dhabi, targeting MERTK-related retinitis pigmentosa using AAV-based delivery. The trial is a collaboration with Cleveland Clinic ...

PCWorld examines when 2.0 speakers outperform 2.1 systems, focusing on budget constraints, space limitations, and audio preferences for different users. 2.0 systems offer compact, cost-effective ...

VANCOUVER, British Columbia--(BUSINESS WIRE)--$ABCL--AbCellera (Nasdaq: ABCL) today announced that the first patients have been dosed in the Phase 2 portion of its ...

Systemic Olvi-Vec administration in lung cancer trials shows feasibility, tolerability, and promising clinical responses in heavily pretreated patients. OLVI-VEC-SCLC-202 trial in SCLC shows a 33% ...